Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Nov;171(5):1221-5.
doi: 10.1016/0002-9378(94)90136-8.

Nafarelin therapy in endometriosis: long-term effects on bone mineral density

E S Orwoll  1 , A A Yuzpe, K A Burry, L Heinrichs, V C Buttram Jr, M D Hornstein
Affiliations
Clinical Trial

Nafarelin therapy in endometriosis: long-term effects on bone mineral density

E S Orwoll et al. Am J Obstet Gynecol. 1994 Nov.

Abstract

Objective: The study intent was to examine long-term effects on bone mass of 3 or 6 months of nafarelin therapy for endometriosis.

Study design: Women with established endometriosis (N = 173) were randomized to receive nafarelin (200 micrograms intranasally twice a day) for either 3 or 6 months in a double-blind fashion. Bone mineral density was measured by dual energy x-ray absorptiometry at lumbar spine and proximal femoral sites for 18 months.

Results: Bone mineral density declined at spinal and femoral sites similarly in both 3- and 6-month treatment groups. There was a partial, but incomplete, return to baseline levels after 12 to 15 months of follow-up. The recovery of bone mass was more complete in subjects with higher dietary calcium intakes.

Conclusion: Nafarelin therapy for endometriosis results in a sustained loss of spinal and femoral bone density, particularly in women with lower calcium intakes.

PubMed Disclaimer

Publication types